Ex parte LEANDER et al. - Page 4

          Appeal No. 1996-0682                                                        
          Application 08/127,121                                                      

          1-7 and lines 24-31.  To avoid unwanted side effects when                   
          treating psoriasis, appellants state that the concentration of              
          podophyllotoxin should be kept low, and a preparation                       
          containing about 0.1 weight percent is preferred.  See the                  
          specification at page 2, lines 8-15.                                        
               As evidence of obviousness of the claimed subject matter               
          on appeal, the examiner relies on the combined disclosures of               
          Leander, Makino, Evers, and Jacobsen.  Appellants characterize              
          Leander, the examiner’s “primary reference," as disclosing a                
          method of treating psoriasis using a podophyllotoxin cream                  
          composition, “but no specific pharmaceutical preparation is                 
          described.”  See the specification at page 1, lines 24-27.  In              
          fact, Leander describes a detailed clinical investigation                   
          using creams containing 0.1%, 0.25%, and 0.5% podophyllotoxin               
          for treatment of 152 patients afflicted with psoriasis                      
          vulgaris which produced “statistically significant                          
          improvements” at all three dosage levels.  See Leander at                   
          column 4, line 21 to column                                                 
          5, line 8.  Although the Leander reference does not                         
          specifically describe how the prior art podophyllotoxin creams              
          were made or the specific ingredients included therein, the                 

Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  Next 

Last modified: November 3, 2007